Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 331.5 INR 2.6% Market Closed
Market Cap: 398B INR
Have any thoughts about
Biocon Ltd?
Write Note

Operating Margin
Biocon Ltd

10.1%
Current
12%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.1%
=
Operating Profit
15B
/
Revenue
148.9B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Biocon Ltd
NSE:BIOCON
398B INR
10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-22%
Country IN
Market Cap 398B INR
Operating Margin
10%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 116.2B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 81.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.8B EUR
Operating Margin
-22%
No Stocks Found

Biocon Ltd
Glance View

Market Cap
398B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
455.48 INR
Undervaluation 27%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.1%
=
Operating Profit
15B
/
Revenue
148.9B
What is the Operating Margin of Biocon Ltd?

Based on Biocon Ltd's most recent financial statements, the company has Operating Margin of 10.1%.